• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Lumicell aims $29m Series C at pivotal breast cancer trial and expansion into other cancers

December 7, 2017 By Sarah Faulkner

With $28.7 million from a recently-closed Series C round, Lumicell reported today that it plans to launch a pivotal trial of its image-guided cancer surgery tech in breast cancer.

The Wellesley, Mass.-based company added that it hopes to expand its clinical program into other solid tumor cancers, including lung, ovarian and brain cancer.

The company’s Lum system is currently being studied in patients with breast cancer, prostate cancer, colorectal, esophageal and pancreatic cancers.

The drug-device product combines a fluorescent optical contrast agent with a hand-held imaging device that scans cavity walls to detect leftover cancer cells. The Lum system also includes decision software that displays the image in real-time on a monitor, guiding the surgeon to remove cancerous tissue. The company is positioning its technology as a way to boost outcomes and cut costs by reducing the number of repeat surgeries.

“We are grateful for the funding and support from our investors which will be used to drive completion of our breast cancer studies as well as expand the Lum system pipeline into additional cancer indications, with a focus on driving innovation to improve patient outcomes,” CEO Kelly Londy said in prepared remarks. “We look forward to several key development milestones, over the next year, as our platform moves into the next stages and our company grows.”

Existing and new investors participated in the company’s recent Series C round, including Launch Capital and BlueIO.

“We are pleased to support Lumicell in its drive toward providing cancer surgeons with a single integrated system to detect and remove cancer cells in real-time during surgery and potentially reducing the need for repeat surgeries,” Launch Capital’s founder & chairman Elon Boms said.

“The clinical applications for the Lum system are far-reaching and we look forward to working with the Lumicell team to expand this potential game-changing advance in cancer surgery and beyond with their innovative platform. We are very proud to be involved in supporting Lumicell’s immediate go to market growth phase as they work to advance clinical care for all cancer patients,” Dave Furneaux, CEO of BlueIO and managing general partner of Kodiak Venture Partners, added.

Also today, Lumicell touted data from a Phase II trial showing that the Lum system could detect all breast cancer sub-types in patients undergoing lumpectomy surgery. The technology correctly identified residual cancer within the tumor cavity in all 45 of the trial’s participants, the company reported.

“Currently, up to 40% of breast cancer lumpectomy patients have positive margins that require surgical re-excision,” Dr. Barbara Smith, director of the Breast Program at Massachusetts General Hospital and professor of surgery at Harvard Medical School, said in prepared remarks. “By providing instantaneous identification of residual tumor in the lumpectomy cavity, the Lum system has the potential to provide surgeons with enhanced information to improve care for their breast cancer patients.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Funding Roundup, Oncology Tagged With: Lumicell

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS